Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 2-benzoxazolamine, 5-(4-amino-1-(1-methylethyl)-1h-pyrazolo(3,4-d)pyrimidin-3-yl)-
2. 3-(2-amino-1,3-benzoxazol-5-yl)-1-isopropyl-1h-pyrazolo(3,4-d)pyrimidin-4-amine
3. Cb-228
4. Ink128
5. Mln-0128
6. Mln0128
7. Tak-228
1. 1224844-38-5
2. Ink-128
3. Mln0128
4. Ink 128
5. Ink128
6. Tak-228
7. Mln-0128
8. Ink 128 (mln0128)
9. 5-(4-amino-1-isopropyl-1h-pyrazolo[3,4-d]pyrimidin-3-yl)benzo[d]oxazol-2-amine
10. Sapanisertib (mln0128)
11. Jgh0df1u03
12. 3-(2-amino-5-benzoxazolyl)-1-(1-methylethyl)-1h-pyrazolo[3,4-d]pyrimidin-4-amine
13. 5-(4-amino-1-propan-2-ylpyrazolo[3,4-d]pyrimidin-3-yl)-1,3-benzoxazol-2-amine
14. 5-(4-amino-1-isopropyl-1h-pyrazolo[3,4-d]-pyrimidin-3-yl)benzo[d]oxazol-2-amine
15. 5-(4-azanyl-1-propan-2-yl-pyrazolo[3,4-d]pyrimidin-3-yl)-1,3-benzoxazol-2-amine
16. Sapanisertib [inn]
17. Unii-jgh0df1u03
18. 1h-pyrazolo[3,4-d]pyrimidin-4-amine, 3-(2-amino-5-benzoxazolyl)-1-(1-methylethyl)-
19. 1h-pyrazolo(3,4-d)pyrimidin-4-amine, 3-(2-amino-5-benzoxazolyl)-1-(1-methylethyl)-
20. Cb-228
21. Sapanisertib; Ink128
22. Sapanisertib (usan/inn)
23. Sapanisertib [usan:inn]
24. Sapanisertib [usan]
25. Mls006011012
26. Sapanisertib [who-dd]
27. Gtpl7933
28. Schembl7902875
29. Chembl3545097
30. Chebi:91450
31. Ex-a951
32. Ink-128/ink128
33. Bdbm315477
34. Dtxsid401022538
35. Hms3656h12
36. Hms3672c21
37. Ink-128;sapanisertib;mln0128
38. Ink-0128
39. Mfcd22124893
40. Nsc764658
41. Nsc768435
42. Nsc780880
43. S2811
44. Zinc73069271
45. Akos025149512
46. Us10172858, Table 1.1
47. Bcp9000789
48. Ccg-265002
49. Cs-0557
50. Db11836
51. Nsc-764658
52. Nsc-768435
53. Nsc-780880
54. Sb16566
55. 2-benzoxazolamine, 5-(4-amino-1-(1-methylethyl)-1h-pyrazolo(3,4-d)pyrimidin-3-yl)-
56. 3-(2-amino-1,3-benzoxazol-5-yl)-1-isopropyl-1h-pyrazolo(3,4-d)pyrimidin-4-amine
57. Us10172858, Table 1.22
58. Ncgc00346654-01
59. Ncgc00346654-10
60. Ac-26848
61. As-16294
62. Bs170924
63. Hy-13328
64. Smr004702810
65. Bcp0726000086
66. A8551
67. Ft-0700125
68. Sw220210-1
69. D11183
70. Ink-128,cas:1224844-38-5
71. J-004811
72. Q27078072
73. 3-(2-aminobenzo[d]oxazol-5-yl)-1-isopropyl-1h-pyrazolo[3,4-d]pyrimidin-4-amine
74. 5-(4-amino-1-isopropyl-pyrazolo[3,4-d]pyrimidin-3-yl)-1,3-benzoxazol-2-amine
75. 3-(2-amino-1,3-benzoxazol-5-yl)-1-(propan-2-yl)-1h-pyrazolo(3,4-d)pyrimidin-4-amine
76. Fe5
| Molecular Weight | 309.33 g/mol |
|---|---|
| Molecular Formula | C15H15N7O |
| XLogP3 | 1.7 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 2 |
| Exact Mass | 309.13380813 g/mol |
| Monoisotopic Mass | 309.13380813 g/mol |
| Topological Polar Surface Area | 122 Ų |
| Heavy Atom Count | 23 |
| Formal Charge | 0 |
| Complexity | 436 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
94
PharmaCompass offers a list of Sapanisertib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Sapanisertib manufacturer or Sapanisertib supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Sapanisertib manufacturer or Sapanisertib supplier.
PharmaCompass also assists you with knowing the Sapanisertib API Price utilized in the formulation of products. Sapanisertib API Price is not always fixed or binding as the Sapanisertib Price is obtained through a variety of data sources. The Sapanisertib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Sapanisertib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Sapanisertib, including repackagers and relabelers. The FDA regulates Sapanisertib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Sapanisertib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Sapanisertib supplier is an individual or a company that provides Sapanisertib active pharmaceutical ingredient (API) or Sapanisertib finished formulations upon request. The Sapanisertib suppliers may include Sapanisertib API manufacturers, exporters, distributors and traders.
Sapanisertib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Sapanisertib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Sapanisertib GMP manufacturer or Sapanisertib GMP API supplier for your needs.
A Sapanisertib CoA (Certificate of Analysis) is a formal document that attests to Sapanisertib's compliance with Sapanisertib specifications and serves as a tool for batch-level quality control.
Sapanisertib CoA mostly includes findings from lab analyses of a specific batch. For each Sapanisertib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Sapanisertib may be tested according to a variety of international standards, such as European Pharmacopoeia (Sapanisertib EP), Sapanisertib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Sapanisertib USP).
